Drugdevelopment
News, views and contacts from the global Drugdevelopment industry
23 January 2017
DAILY UPDATE
Industry News

UCB and Dermira report positive Phase III trial results of Cimzia to treat chronic plaque psoriasis
UCB and Dermira have reported positive results from its Phase III CIMPACT trial of Cimzia (certolizumab pegol) to treat adult patients with moderate-to-severe chronic plaque psoriasis.

M&As this week: Malin Corporation, Eli Lilly and Company
Irish life sciences company Malin Corporation has acquired 33% stake in Wren Therapeutics with the aim of developing rational therapeutic strategies.

Daiichi Sankyo begins Phase I/II trial of U3-1402 to treat breast cancer in Japan
Japanese-based pharmaceutical company Daiichi Sankyo has begun its Phase I/II trial of U3-1402 to treat patients with HER3-positive metastatic or unresectable breast cancer in Japan.

Deals this week: Takeda Pharmaceutical, HUYA Bioscience International, Egalet
Japanese pharmaceutical company Takeda Pharmaceutical has signed a global agreement with US-based bio-pharmaceutical company Ovid Therapeutics for clinical development and commercialisation of the former’s investigational new drug TAK-935.

Press Releases

Examples of 505(b)(2) Applications
The 505(b)(2) consulting is a mainstay of PDG® activity. What are you doing to hedge against increasingly crowded traditional drug markets?

Measuring the zeta potential of planar surfaces with Zetasizer Nano
Malvern has announced it will host a webinar to discuss how to measure zeta surface potential.

Malvern to Host Webinar on Using Size Exclusion chromatography (SEC) for Protein Characterisation
Size exclusion chromatography (SEC) is a popular analytical technique for studying protein molecular weight, oligomeric state, aggregation, and conjugation.

Gamlen R series Featured in International Journal of Pharmaceutics Paper
'Characterisation of Tableting Properties Measured with a Multi-functional Compaction Instrument for Several Pharmaceutical Excipients and Actual Tablet Formulations' is the latest paper to be published in the International Journal of Pharmaceutics detailing research undertaken using a Gamlen instrument (IJP 510(2016) 195-202).

Malvern Experts to Host 'Festive' Webinar Personally Answering Letters to Father Characterisation
Malvern has announced it will host a live-panel webinar for the discussion of challenges submitted in an online form on the company's website.

White Papers

Using FlexyCUBE in Risk and Quality Analysis
In the first reaction step, an acid is added with constant thermal reduction (TR) control and stirrer...

Using Mophologically Directed Raman Spectroscopy to Detect Counterfeit Drugs
In drug formulation, precise components require careful blending and processing to create a final product that can be administered to deliver the required clinical...

Develop Stable Dispersions in Formulation Development with Zetasizer
Formulation development is a critical activity for many industries, from pharmaceuticals, to paints and coatings. Stability is a crucial element, making a direct impact on performance,...

What to Keep in Mind when Purchasing an Advanced Gel Permeation Chromatography (GPC)/Size Exclusion Chromatography (SEC) System
Buying a new piece of laboratory equipment is always a big decision, with thousands of dollars often being invested on relatively little...

Gamlen Tablet Press Show Similar Capabilities to Fette 2090 High-Speed Tablet Press
Two formulations compacted on the Gamlen Tablet Press have shown matching results with production data obtained on high-speed rotary tablet press Fette...

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Drug Development Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.drugdevelopment-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.